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The purpose of this study was to investigate comparison between oral zinc sulfate and meglumine antimoniate in the treatment of
cutaneous leishmaniasis (CL). So 100 patients with CL were included and randomly divided into two groups. The ﬁrst group was
treated with oral zinc sulfate (10mg/kg/day during 45 days period), and the second group was treated with systemic meglumine
antimoniate (20mg/kg/day intramuscularly for 20 days). Acceptable cure after completing 45 days of followup occurred in 30.2%
of lesions in ﬁrst group, while this was 35.5% for the second group. There is not any signiﬁcant diﬀerence between the two
treatment groups (P = 0.42). Serious side eﬀects resulting in treatment discounting occurred in only meglumine antimoniate
group. Although cure rate of systemic meglumine antimoniate group was better the treatment with zinc sulfate is much easier,
cheaper, more convenient in consumption, safer, and nearly close cure percentage to systemic meglumine antimoniate injections
without serious side eﬀect.
1.Introduction
Cutaneous leishmaniasis (CL) is an important health prob-
lem in endemic area [1]. The incidence of leishmaniasis
is in excess of 400000 cases annually, and 35 millions in
88 countries are at risk [2, 3]. In Iran, Mashhad City of
Khorasan Razavi state is an endemic location for CL, and
the most common form of CL (91% cases) in Mashhad
is the dry form that the caused by Leishmania tropica
[4]. Although CL is a self healing disease, it can result in
disﬁguring scar and long-lasting stigmas, which may destroy
underlying structures like the nose, ear, or exposed sites
of skin that cause psychological suﬀering of patients [3].
Several therapies proposed for CL [1], but between these
treatments pentavalent antimonials, sodium stibogluconate
(pentostam), and meglumine antimoniate (Glucantime;
MA) have maximum eﬃcacy in CL treatment, but serious
side eﬀects, high costs, multiple injections, and incomplete
eﬃcacy make researchers ﬁnd replaceable therapies [5, 6].
Recently zinc sulfate (ZS) activities against L. major and L.
tropica amastigotes were tested in vitro [7]. These results for
CL were conﬁrmed in animal models [8, 9]. Also recently
ZS intralesional injections [10, 11] and oral ZS treatment
[12] showed its eﬀectiveness in CL treatment. With respect
to harmlessness, minimum serious side eﬀect, low cost, and
easyconsumingwayofZSthisstudywasdesignedtoevaluate
comparison of oral ZS and MA in old world cutaneous
leishmaniasis treatment.2 Dermatology Research and Practice
2. Patientsand Methods
This prospective interventional case control clinical trial
was performed in the Dermatology Department, Ghaem
Hospital, Mashhad University of Medical Sciences, between
October 2006 and May 2008. Patients with proven acute CL
by a positive direct smear were selected for this study. A
careful history was taken by the same dermatologist, and
lesions were examined. Inclusion criteria included: duration
of lesions less than 6 months and no antileishmaniasis
treatment received during 2 month ago. Cases of pregnant
or nursing women, patients with hepatic, renal, and heart
diseases were excluded. This protocol was approved by
the Ethical Committee of Mashhad University of Medical
Sciences (MUMS). The planned treatment was explained to
each patient, and consent was taken.
2.1. Treatment and Followup. Using simple randomization
patientswereassignedintotwotreatmentgroups.Firstgroup
received oral zinc sulfate (ZS) in a dose of 10mg/kg/day
during 45-day period before meal in three divided times,
and second group received systemic Meglumine antimoni-
ate (Glucantime; MA, Specia, Paris, France) 20mg/kg/day
intramuscularly for 20 days with a maximum of 3 vials of
Glucantime. Patients were followed up during and at the
end of clinical treatment. Also it was carried out after 45
days from completing treatment period. At each visit all
lesions were reexamined by the same dermatologist. The size
and indurations’ of lesions were measured by palpation and
ruler. In aspect of response to treatment in comparison with
ﬁrst visit patients graded as 4 improvements rate groups: 1:
slight, 2: mild, 3: moderate, and 4: total clearance that in
four respected groups decreased indurations of lesion were
up to 25%, 25–50%, more than 50%, and less than 75% and
75% or more improvement or complete reepithelialization
without any indurations considered as acceptable cure.
2.2. Statistical Analysis. Statistical analyses were performed
using SPSS Software (Version 11.5). Data were expressed as
mean ± SD. Between groups, comparisons were made using
independent t-test and Mann-Whitney test (for numerical
variables) or Chi-square (χ2) and Fisher exact test (for
ordinal variables). A two-tailed P value of P<0.05 was
considered statistically signiﬁcant for all calculations.
3. Results
A total of 115 patients with proven CL participated in this
study. From them 100 patients completed the treatment with
followup visits. Six patients who received systemic MA were
excluded because of side eﬀects that include severe muscular
painandtopicalreactionofinoculationsite(severeerythema
and pruritus). In the present study ﬁve patients in MA group
and4inZSgr oupw er enotfollo w edupforthefulltr eatment
period so these 9 cases also dropped out. Finally 26 patients
with 43 lesions were treated with ZS and 74 patients with 127
lesions with MA.
The characteristics of CL studied patients are presented
in Table 1. There is no signiﬁcant correlation between
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Figure 1: Response into two diﬀerent treatments (ZS and MA) in
CL studied patients after completing treatment. There is not any
statistically signiﬁcant diﬀerence between MA and ZS treatment
groups in acceptable cure (P = 0.44).
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Figure 2: Response into two diﬀerent treatments (ZS and MA)
in CL studied patients after 45 days of followup. There is not any
statistically signiﬁcant diﬀerence between MA and ZS treatment
groups in acceptable cure (P = 0.42).
improvement rate and age of patients (P = 0.16) and
durationoflesion(P = 0.09).Incompletetreatment(6cases)
b e c a u s eo fs i d ee ﬀects was seen just in MA group, and ZS
had not any signiﬁcant side eﬀects (P<0.05). Number
of CL lesions localization in studied patients between two
diﬀerent treatments is shown in Table 2. Also there is
normal distribution between CL involved sites (trunk, head
and neck, upper limb, and lower limb) into two diﬀerent
treatment groups (ZS and MA) (P<0.05).
Figures 1 and 2 show responding into ZS and MA
treatments in CL studied patients after completing treatment
and after 45 days of followup, respectively. Improvement rate
as previously described graded into 4 groups (slight, mild,Dermatology Research and Practice 3
Table 1: General characteristics of CL studied patients between two treatment groups (MA and ZS).
Drug Patients Age, year (mean ± SD) Males Females No. of lesions Duration of lesions (month)
MA 74 25 ± 19 39 35 127 4 ± 1.5
ZS 26 32 ± 23 11 15 43 4.5 ± 1.5
Table 2: Number of CL lesions in diﬀerent sites between two
treatment groups.
Lesion site ZS (10mg/kg/day) MA (20mg/kg/day)
Head and neck 19 (44.3%) 56 (44.1%)
Upper limb 18 (44.9%) 56 (44.1%)
Lower limb 5 (11.6%) 14 (11%)
Trunk 1 (2.3%) 1 (0.8%)
Frequency percentages in CL studied patients (%).
moderate, and acceptable cure). There is not any statistically
signiﬁcant diﬀerence between two treatments for acceptable
cure after completing and 45 days of followup of treatment
(P = 0.44 and P = 0.42, resp.).
4. Discussion
Oral zinc sulfate had been used for several skin disorders
for many years with few side eﬀects. Recently publications
showed that promastigotes and amastigotes of L. major and
L. tropica were sensitive to ZS in vitro and in animals [7].
Zinc level is important for T cell, neutrophil, and natural
killer cell function. The antileishmanial eﬀect of zinc may
result from the inhibition of enzymes that are necessary for
the parasites, and these eﬀects are dose dependent [13]. Our
study results showed that both treatments (ZS and MA) have
moderate cure rate in CL. Acceptable cure at the end of
completing and after 45 days of followup of treatment for
MA was 17% and 35%, respectively, while it was 14% and
30.2% for ZS treatment, respectively.
In Iraq, Sharquie et al. reported that the eﬃcacy of
intralesionally and oral ZS was 94.8% and 96.9%, respec-
tively [10, 12]. Iraji et al. in comparative study reported that
cure rate of intralesionally ZS solution was 83.8% and 60%
for MA. Cure rate of oral ZS according to ﬁrst CL treatment
in Mashhad (our studied area) was 9% [14] and 34.5% [15]
and 37.9% [16] for systemic MA.
Eﬃcacy of ZS in Yazdanpanah et al.’ [14] study as the
ﬁrst pilot study in Mashhad on 22 cases was 9% without
control group that was in contrast with previously reported
study by Sharquie et al. [12], so, for better decisions about
ZS eﬀectiveness, we decided to evaluate ZS eﬃcacy and
comparison with MA.
In our study the eﬃcacy of MA was more than that of ZS
aftercompletingand45daysoffollowup,butthereisnotany
signiﬁcant diﬀerence between two treatments as MA and ZS
treatments had nearly equal eﬃcacy for acceptable cure after
completing and 45 days of followup after treatment. This is
comparable to previous studies in Mashhad [15, 16], while
Iraji et al. reported that eﬃcacy of intralesional ZS was more
than MA [11]. These diﬀerences in treatment improvement
results may be caused by the diﬀerence between way of
treatmentmethodandalsocompletetreatmentasconsidered
total clearance is diﬀerent, as our results (35% for MA and
17% for ZS treatment) are so close to previous studies in
Mashhad (∼36.2% for MA and 9% for ZS) [15, 17]. Second
probability factors for these seen diﬀerences may be due
to parasite strains. Most of CL in Mashhad was caused
by L. tropica [17], while in other reported studies on ZS
treatment the most lesions were caused by L. major [10–
12]. Finally anti CL therapeutic resistance (especially MA)
was discussed-problem [18] so there is probability of ZS
resistance in our studied area, but this needs to be conﬁrmed
by greater number of CL patient’s population. In spite of
drug diﬀerences, dietary patients regimes especially phytate
enriched diets (that interfere with zinc absorption) aﬀect
oral ZS intake. Iranians have diets with high phytates, so this
may be one eﬀective factor to this improvement response in
comparison with other studies [19].
This present study indicates that systemic MA injections
in CL treatment were better than ZS but oral ZS is cheaper,
more convenient is consumption, and nearly close cure
percentage to systemic MA injections without serious side
eﬀects. Because there are no cited studies about therapeutic
eﬀect of oral ZS on CL caused by L. tropica, we supposed that
ZS therapeutic eﬀects should be conﬁrmed by greater sample
volume.
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